Septerna to Participate in the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Septerna, a biotechnology company discovering and advancing novel, oral small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced that management will participate in the Jefferies Global Healthcare Conference in New York on Tuesday, June 4, 2024.

About Septerna

Septerna, Inc. is a biotechnology company focused on advancing novel, oral small molecule medicines targeting the entire class of G protein-coupled receptors (GPCRs). The company’s Native Complex PlatformTM recapitulates GPCRs with their native structure, function, and dynamics outside of the cellular environment to rapidly apply new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. Septerna was launched in 2022 by scientific founders who have made groundbreaking GPCR discoveries. For more information, please visit www.septerna.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240528125487/en/

Investor Contact
Renee Leck
THRUST Strategic Communications
[email protected]

Media Contact
Cory Tromblee
Scient PR
[email protected]

Source: Septerna

You May Also Be Interested In

• Everbridge and Arcadis Partner to Help Organizations Assess and Manage Climate Risk
• JEOL: Launch of the New Benchtop Scanning Electron Microscope “JCM-7000Plus NeoScope™”
• Resolution Therapeutics partners with the Blood Centers of America, Inc. to support broad patient access to its experimental Regenerative Macrophage Therapy in the U.S.